Success for Pfizer’s Trastuzumab Biosimilar in Phase 3 Clinical Trials


Today, Pfizer reported that their trastuzumab biosimilar to Roche’s Herceptin® has shown equivalence in a Phase 3 clinical trial measuring objective response rate (ORR) when taken in combination with paclitaxel to treat HER-positive metastatic breast cancer patients.

Pfizer also reported success in a separate study, REFLECTIONS B3271004, evaluating this biosimilar in early breast cancer patients. Clinical trials and development of Pfizer’s trastuzumab product are ongoing.

Stay tuned for more updates from Big Molecule Watch.

Written by:


Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.